We are upgrading the repository! A content freeze is in effect until December 6, 2024. New submissions or changes to existing items will not be allowed during this period. All content already published will remain publicly available for searching and downloading. Updates will be posted in the Website Upgrade 2024 FAQ in the sidebar Help menu. Reach out to escholarship@umassmed.edu with any questions.

Show simple item record

dc.contributor.authorEichinger, Katy
dc.contributor.authorHeatwole, Chad
dc.contributor.authorHeininger, Susanne
dc.contributor.authorStinson, Nikia
dc.contributor.authorMatichak Stock, Carly
dc.contributor.authorGrosmann, Carla
dc.contributor.authorWagner, Kathryn R.
dc.contributor.authorTawil, Rabi
dc.contributor.authorStatland, Jeffrey M.
dc.contributor.authorFSHD Clinical Trials Research Network
dc.date2022-08-11T08:11:04.000
dc.date.accessioned2022-08-23T17:30:42Z
dc.date.available2022-08-23T17:30:42Z
dc.date.issued2017-03-01
dc.date.submitted2017-04-12
dc.identifier.citationMuscle Nerve. 2017 Mar;55(3):333-337. doi: 10.1002/mus.25251. Epub 2016 Dec 5. <a href="https://doi.org/10.1002/mus.25251">Link to article on publisher's site</a>
dc.identifier.issn0148-639X (Linking)
dc.identifier.doi10.1002/mus.25251
dc.identifier.pmid27421252
dc.identifier.urihttp://hdl.handle.net/20.500.14038/50568
dc.description.abstractINTRODUCTION: In preparation for future clinical trials, we determined the reliability, relationship to measures of disease severity, and consistency across sites of the 6 Minute Walk Test (6MWT) in patients with facioscapulohumeral muscular dystrophy (FSHD). METHODS: Genetically defined and clinically affected FSHD participants at 2 sites performed the 6MWT, the Timed Up and Go, and the 30 foot Go/Timed 10 meter test as measures of mobility using standard procedures. RESULTS: Eight-six participants representing the full range of severity performed the 6MWT. The mean 6MWT distance was 404.3 meters (SD 123.9), with no difference between sites. The 6MWT was reliable (n = 25; intraclass correlation coefficient = 0.99) and demonstrated moderate to strong correlations with lower extremity strength, functional outcomes, and FSHD Clinical Score. CONCLUSIONS: The 6MWT is reliable and is associated with other measures of FSHD disease severity. Future directions include assessing its sensitivity to disease progression. .
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=27421252&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttps://doi.org/10.1002/mus.25251
dc.subject6 Minute Walk Test
dc.subjectclinical trials
dc.subjectfacioscapulohumeral muscular dystrophy
dc.subjectneuromuscular disease
dc.subjectoutcome measures
dc.subjectCell Biology
dc.subjectDevelopmental Biology
dc.subjectMolecular Biology
dc.subjectMolecular Genetics
dc.subjectMusculoskeletal Diseases
dc.subjectNervous System Diseases
dc.titleValidity of the 6 minute walk test in facioscapulohumeral muscular dystrophy
dc.typeJournal Article
dc.source.journaltitleMuscle and nerve
dc.source.volume55
dc.source.issue3
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/wellstone_pubs/37
dc.identifier.contextkey10009687
html.description.abstract<p>INTRODUCTION: In preparation for future clinical trials, we determined the reliability, relationship to measures of disease severity, and consistency across sites of the 6 Minute Walk Test (6MWT) in patients with facioscapulohumeral muscular dystrophy (FSHD).</p> <p>METHODS: Genetically defined and clinically affected FSHD participants at 2 sites performed the 6MWT, the Timed Up and Go, and the 30 foot Go/Timed 10 meter test as measures of mobility using standard procedures.</p> <p>RESULTS: Eight-six participants representing the full range of severity performed the 6MWT. The mean 6MWT distance was 404.3 meters (SD 123.9), with no difference between sites. The 6MWT was reliable (n = 25; intraclass correlation coefficient = 0.99) and demonstrated moderate to strong correlations with lower extremity strength, functional outcomes, and FSHD Clinical Score.</p> <p>CONCLUSIONS: The 6MWT is reliable and is associated with other measures of FSHD disease severity. Future directions include assessing its sensitivity to disease progression. .</p>
dc.identifier.submissionpathwellstone_pubs/37
dc.contributor.departmentWellstone Center for FSHD
dc.source.pages333-337


This item appears in the following Collection(s)

Show simple item record